Strategic Initiative

Slingshot members are tracking this corporate initiative:

Gilead Sciences (GILD) and Tango Therapeutics to Expand Strategic Oncology Collaboration

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details The collaboration excludes Tango’s lead programs, including one program that is expected to be in investigational new drug (IND) applicatation-enabling studies next year. Tango also retains the rights to identify targets outside the immune evasion space as it continues to build its wholly owned pipeline.
Under the terms of the collaboration, Gilead will make a $125 million upfront payment to Tango and a $20 million equity investment in the company. In addition, Gilead will have the right to option up to 15 programs over the seven-year collaboration for up to $410 million per program in opt-in, extension and milestone payments. Tango will also be eligible to receive up to low double-digit tiered royalties on net sales. For those products that Tango opts to co-develop and co-promote, the parties will equally split profits and losses, as well as development costs, in the U.S., and Tango will be eligible to receive milestone payments and royalties on ex-U.S. sales.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Aug 17, 2020
Projected Implementation:
Q3, 2020
Relevance Tracked Until:
Q4, 2020
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Oncology, Immuno-oncology